Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX83 Phase 2b to assess efficacy, safety, and immunogenicity 2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious …
Archives de l’auteur : Marianne Duparc
BARDA provides Osivax with $19.5 million for universal flu vaccine
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …
France’s Osivax wins $19.5M BARDA award for universal flu vaccine
Osivax publishes positive results from trial of influenza vaccine candidate
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company …
Osivax publishes phase 2a results supporting dual flu vaccine approach
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates First Close of Series B financing raises €10 million Meiji Seika Pharma Co., Ltd joins as new international investor Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates Lyon, France – March 4, 2025 – Osivax, a …
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …